Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

Table 5 List of candidates selected in the 3D Experiment.

Gene	Master protein	Protein name	Annotated sequence	Ref	Charge
APMAP	Q9HDC9	Adipocyte plasma membrane-associated protein	AGPNGTLFVADAYK	[30]	2
AZU1	P20160	Azurocidin	FVNVTVTPEDQCRPNNVCTGVLTR	[25]	3
CHL1	O00533	Neural cell adhesion molecule L1-like protein	ISGVNLTQK	BioGPS	2
CHL1	O00533	Neural cell adhesion molecule L1-like protein	IIPSNNSGTFR	BioGPS	2
CSPG4	Q6UVK1	Chondroitin sulfate proteoglycan 4	LDPTVLDAGELANR	BioGPS	2
CTSD	P07339	Cathepsin D	GSLSYLNVTR	[30]	2
ELANE	P08246	Neutrophil elastase	VVLGAHNLSR	[25]	3
FCN3	O75636	Ficolin-3	VELEDFNGNR	[16]	2
IL6ST	P40189	Interleukin-6 receptor subunit beta	LTVNLTNDR	[30]	2
LAMP2	P13473	Lysosome-associated membrane glycoprotein 2	VQPFNVTQGK	[30]	2
LTF	P02788	Lactotransferrin	NGSDCPDKFCLFQSETK	[25]	3
MRC2	Q9UBG0	C-type mannose receptor 2	VTPACNTSLPAQR	[16]	2
POSTN	Q15063	Periostin	EVNDTLLVNELK	[30]	2
RNASE1	P07998	Ribonuclease pancreatic	SNSSMHITDCR	[16]	3
TIMP1	P01033	Metalloproteinase inhibitor 1	FVGTPEVNQTTLYQR	[30]	2
VNN1	O95497	Pantetheinase	MTGSGIYAPNSSR	BioGPS	2
VNN1	O95497	Pantetheinase	LTGVAGNYTVCQK	BioGPS	2
MASP1	P48740	Mannan-binding lectin serine protease 1	NNLTTYK	BioGPS	2

ISSN: 1559-0275